EV Nickel Inc. | Finanzwire

Basculer en Français

10591	Companies
224565	Keywords
153304	Articles
118791	Press releases

Home
Companies
EV Nickel Inc.

BRIEF

published on 09/04/2024 at 13:05, 1 year 9 months ago

EV Nickel Confirms High-Grade Nickel at Langmuir #2 Intersecting Nickel Grades from 1.07% to 5.11%

Exploration Nickel Assay Results High-grade Langmuir #2
PRESS RELEASE

published on 09/04/2024 at 13:00, 1 year 9 months ago

EV Nickel Confirms High-Grade Nickel at Langmuir #2 Intersecting Nickel Grades from 1.07% to 5.11%
EV Nickel Inc. reports high-grade nickel intercepts including 5.11% Ni in Langmuir #2 Nickel Zone, with assay results indicating high nickel tenor. Company plans further drilling to advance Canadian nickel supply chain

Drilling Program Assay Results EV Nickel Inc. High-grade Nickel Canadian Nickel Supply Chain
BRIEF

published on 08/16/2024 at 10:46, 1 year 10 months ago

First Berlin Equity Research Reaffirms BUY Rating for APONTIS PHARMA AG

First Berlin Equity Research Buy Recommendation APONTIS PHARMA AG H1/24 Results Single Pill Business
PRESS RELEASE

published on 08/16/2024 at 10:41, 1 year 10 months ago

Original-Research: APONTIS PHARMA AG (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research recommends buying APONTIS PHARMA AG shares with a target price of €17 after solid H1/24 results and positive outlook. Analyst Christian Orquera maintains his BUY rating

First Berlin Equity Research Buy Recommendation APONTIS PHARMA AG H1/24 Results Christian Orquera
BRIEF

published on 08/09/2024 at 07:35, 1 year 10 months ago

APONTIS PHARMA Reports Strong Half-Year Growth in 2024

Revenue Growth APONTIS PHARMA Single Pill Combinations EBITDA Improvement Novartis Cooperation
PRESS RELEASE

published on 08/09/2024 at 07:30, 1 year 10 months ago

APONTIS PHARMA with profitable revenue growth for Single Pill combinations in the first half of 2024 – forecast for the full year confirmed
APONTIS PHARMA reports profitable revenue growth with Single Pill combinations in the first half of 2024. Forecast for full year 2024 confirmed. Earnings and sales improvements noted

EBITDA Revenue Growth Forecast APONTIS PHARMA Single Pill Combinations
BRIEF

published on 06/27/2024 at 07:35, 1 year 11 months ago

APONTIS PHARMA AG Appoints CFO Thomas Zimmermann to Management Board

Management Board APONTIS PHARMA ESG Strategy Thomas Zimmermann Single Pill
PRESS RELEASE

published on 06/27/2024 at 07:30, 1 year 11 months ago

APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board with a view to the strategic development of the Company
APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board to enhance strategic development, internationalization, and ESG strategy. CFO brings strong financial expertise

CFO Strategic Development Management Board APONTIS PHARMA AG Thomas Zimmermann
BRIEF

published on 06/24/2024 at 11:06, 1 year 11 months ago

APONTIS PHARMA AG Receives Buy Rating from First Berlin Equity Research

BUY Rating APONTIS PHARMA AG Single Pills Turnaround Story Cardiovascular And Respiratory Drugs
PRESS RELEASE

published on 06/24/2024 at 11:01, 1 year 11 months ago

Original-Research: APONTIS PHARMA AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research initiates coverage on APONTIS PHARMA AG with a Buy rating and EUR 17.00 price target. Apontis focuses on cardiovascular and respiratory drugs in Germany, led by CEO Wohlschlegel to drive efficiency and growth

First Berlin Equity Research APONTIS PHARMA AG Specialty Pharmaceuticals Turnaround Story Single Pill Therapies

Accesswire

Published on 06/17/2026 at 22:50, 17 minutes ago

International Battery Metals Ltd. Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results
Published on 06/17/2026 at 22:30, 37 minutes ago

Innodata Appoints Jayant Chauhan as Chief Financial Officer
Published on 06/17/2026 at 16:55, 6 hours 12 minutes ago

Snipp Interactive Named a Representative Vendor in the Gartner(R) 2026 Market Guide for Loyalty Program Vendors
Published on 06/17/2026 at 16:45, 6 hours 22 minutes ago

Nymox's Nymozarfex(TM) Newly Available for Prostate Treatments for Medical Tourists in Collaboration with the Global Alliance of Regenerative Medicine on Roatan Island in the Caribbean
Published on 06/17/2026 at 14:30, 8 hours 37 minutes ago

Solitario Advances 2026 Ponderosa Drilling Program

View all ACCESSWIRE

EQS Group

Published on 06/17/2026 at 21:40, 1 hour 27 minutes ago

Tinnitus Quest Builds Momentum with Oxford Research Study, New Funding Call, and Second Tinnitus Hackathon
Published on 06/17/2026 at 19:10, 3 hours 57 minutes ago

Africa Finance Corporation and Leading Italian Institutions Sign Strategic Cooperation Agreements at AFC-Italy Forum to Mobilise Capital and Accelerate Industrial Development Across Africa
Published on 06/17/2026 at 18:40, 4 hours 27 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 06/17/2026 at 18:36, 4 hours 31 minutes ago

BILENDI: Bilendi announces that Euroland Corporate has initiated coverage of its shares
Published on 06/17/2026 at 18:23, 4 hours 44 minutes ago

EQS-Adhoc: Ludwig Beck am Rathauseck-Textilhaus Feldmeier AG: Conclusion of a delisting agreement with Bayerische Gewerbebau AG

Les Echos

Published on 06/17/2026 at 17:40, 5 hours 27 minutes ago

Report on share repurchases from 10 to 16 June 2026
Published on 06/17/2026 at 08:45, 14 hours 22 minutes ago

Air Liquide is awarded its largest-ever contract in Spain to care for 90,000 patients living with respiratory conditions at home
Published on 06/16/2026 at 11:44, 1 day 11 hours ago

Guillemot Corporation S.A. | Weekly report share buyback from June 8 to June 12 2026
Published on 06/15/2026 at 23:00, 2 days ago

BIOPHYTIS ANNOUNCES THE TEMPORARY SUSPENSION OF THE TRADING OF ITS SHARES
Published on 06/15/2026 at 18:57, 2 days 4 hours ago

Reporting on share buyback transactions carried out between June 8 and June 11, 2026

View all LES ECHOS COMFI WIRE